Exploring Differential Baseline Expression of Inflammatory Markers in Patients with Severe Depression and Variable Response to Intermittent Theta Burst Stimulation

Bruno Pedraz-Petrozzi[1,2,3,4,*], Jonas Wilkening[5], Nicole Ziegler[6], Martijn Arns[7,8], Alexander Sartorius[1,2,4], Roberto Goya-Maldonado[5]

[1]Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

[2]German Center for Mental Health (DZPG), partner site Mannheim, Germany.

[3] Research Group of Stress-related Disorders, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

[4]Research Group Brain Stimulation, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

[5]Laboratory of Systems Neuroscience and Imaging in Psychiatry (SNIP-Lab), Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany

[6]Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany

[7]Brainclinics Foundation, Nijmegen, The Netherlands

[8]Stanford Brain Stimulation Lab, Stanford University, Palo Alto, United States of America.

[*]**Corresponding author:**

Dr. Bruno Pedraz-Petrozzi, Ph.D.
Central Institute of Mental Health (CIMH)
Department of Psychiatry and Psychotherapy
J5
D-68159 Mannheim
Germany
Phone: +49 621 1703 4363
Email: bruno.pedraz@zi-mannheim.de
ORCID: 0000-0002-4119-971X

Authors' ORCID
Jonas Wilkening, ORCID: 0009-0000-3539-1900
Nicole Ziegler, ORCID: 0009-0002-4626-8793
Martjin Arns, ORCID: 0000-0002-0610-7613
Alexander Sartorius, ORCID: 0000-0002-1243-3693
Roberto Goya-Maldonado, ORCID: 0000-0002-7368-1332

Abstract Word Count: 248 words
Total Word Count: 7322 words

Keywords (MeSH terms): Major Depressive Disorder; Inflammation; rTMS; iTBS; Cytokines; Biomarkers; Treatment Response; Clustering Analysis; Immune Dysregulation

Ethics Approval and Consent to Participate: The study protocol was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the University Medical Center Göttingen (UMG). All participants provided both verbal and written informed consent after receiving a full explanation of the study procedures.

Consent for Publication: Not applicable.

Availability of Data and Materials: The data supporting the findings of this study are not publicly available due to European Union data protection regulations. However, data may be made available upon reasonable request from the corresponding author, provided appropriate legal and ethical conditions are met.

Competing Interests: The authors declare that they have no competing interests.

Funding: This project received financial support from the German Federal Ministry of Education and Research (*Bundesministerium für Bildung und Forschung, BMBF: 01 ZX 1507*, ''PreNeSt - e:Med'') and the foundation *Immunität und Seele* (Prof. Dr. Norbert Müller *https://immunitaet-und-seele.de/*). The funders had no role in the study design, data collection, analysis, interpretation, or manuscript preparation.

Employment: None of the authors was employed or contracted by any organization that could gain or lose financially from the publication of this manuscript.

Acknowledgements: This work was supported by the German Federal Ministry of Education and Research (*Bundesministerium für Bildung und Forschung, BMBF: 01 ZX 1507*, ''PreNeSt - e:Med'') and the to the foundation *Immunität und Seele (https://immunitaet-und-seele.de/)*. The authors thank the team of Dr. Nicole Ziegler (Fraunhofer Institute for Translational Medicine and Pharmacology, Frankfurt am Main, Germany) for their assistance in analyzing blood samples using proteomics panels.

Personal Financial Interests: The authors did not receive any form of financial compensation (e.g., salaries, stocks, consulting fees) from commercial entities related to this research.

Statement: During the preparation of this manuscript, the authors used Grammarly Inc. and ChatGPT to assist with language refinement and grammar correction. Elicit was used to support the literature search. All content was critically reviewed and edited by the authors, who take full responsibility for the final version of the manuscript.

Declarations of Interest: Bruno Pedraz acknowledges receiving a Seed Money for Research grant from the Central Institute of Mental Health and receiving a grant from the foundation *Immunität und Seele*. Roberto Goya-Maldonado acknowledges receiving a grant from the

ABBREVIATION LIST

4E-BP1	Eukaryotic Translation Initiation Factor 4E-Binding Protein 1
ADA	Adenosine Deaminase
ANOVA	Analysis of Variance
ARTN	Artemin
AXIN1	Axis Inhibition Protein 1
Beta-NGF	Beta Nerve Growth Factor
BMI	Body Mass Index
CASP-8	Caspase 8
CCL11	C-C Motif Chemokine Ligand 11 (Eotaxin-1)
CCL19	C-C Motif Chemokine Ligand 19
CCL20	C-C Motif Chemokine Ligand 20
CCL23	C-C Motif Chemokine Ligand 23
CCL25	C-C Motif Chemokine Ligand 25
CCL28	C-C Motif Chemokine Ligand 28
CCL3	C-C Motif Chemokine Ligand 3
CCL4	C-C Motif Chemokine Ligand 4
CD244	CD244 Molecule (2B4)
CD40	CD40 Molecule
CD5	CD5 Molecule
CD6	CD6 Molecule
CD8A	CD8a Molecule
CDCP1	CUB Domain Containing Protein 1
CNS	Central Nervous System
CRP	C-Reactive Protein
CSF-1	Colony Stimulating Factor 1
CST5	Cystatin D
CX3CL1	CX3C Motif Chemokine Ligand 1 (Fractalkine)
CXC	C-X-C Motif Chemokine Family
CXCL	C-X-C Motif Chemokine Ligand (e.g., CXCL1, CXCL5, CXCL6, CXCL11)
CXCL1	C-X-C Motif Chemokine Ligand 1
CXCL10	C-X-C Motif Chemokine Ligand 10
CXCL11	C-X-C Motif Chemokine Ligand 11
CXCL5	C-X-C Motif Chemokine Ligand 5

CXCL6	C-X-C Motif Chemokine Ligand 6
CXCL9	C-X-C Motif Chemokine Ligand 9
DEPs	Differentially Expressed Proteins
DLPFC	Dorsolateral Prefrontal Cortex
DNER	Delta/Notch-Like EGF Repeat Containing
DSM-5	Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
ECT	Electroconvulsive Therapy
EDTA	Ethylenediaminetetraacetic Acid
EN-RAGE	Extracellular Newly Identified RAGE-Binding Protein (S100A12)
FDA	U.S. Food and Drug Administration
FDR	False Discovery Rate
FGF-19	Fibroblast Growth Factor 19
FGF-21	Fibroblast Growth Factor 21
FGF-23	Fibroblast Growth Factor 23
FGF-5	Fibroblast Growth Factor 5
Flt3L	FMS-like Tyrosine Kinase 3 Ligand
GDNF	Glial Cell Line-Derived Neurotrophic Factor
gp130	Glycoprotein 130
GPCR	G-Protein–Coupled Receptor
HGF	Hepatocyte Growth Factor
HPA	Hypothalamic–Pituitary–Adrenal Axis
IFNγ	Interferon Gamma
IL	Interleukin (e.g., IL-6, IL-8, IL-10, IL-13)
IL10RA	Interleukin 10 Receptor Subunit Alpha
IL10RB	Interleukin 10 Receptor Subunit Beta
IL12B	Interleukin 12 Subunit Beta
IL15RA	Interleukin 15 Receptor Alpha
IL17A	Interleukin 17A
IL17C	Interleukin 17C
IL18R1	Interleukin 18 Receptor 1
IL1α	Interleukin 1 Alpha
IL1β	Interleukin 1 Beta
IL20	Interleukin 20
IL20RA	Interleukin 20 Receptor Alpha

IL22RA1	Interleukin 22 Receptor Subunit Alpha 1
IL24	Interleukin 24
IL2RB	Interleukin 2 Receptor Subunit Beta
IL6	Interleukin 6
IL10	Interleukin 10
IL13	Interleukin 13
IL18	Interleukin 18
IL2	Interleukin 2
IL33	Interleukin 33
IL4	Interleukin 4
IL5	Interleukin 5
IL7	Interleukin 7
IL8	Interleukin 8
ITAC	Interferon-inducible T-cell Alpha Chemoattractant
iTBS	Intermittent Theta Burst Stimulation
JAK/STAT	Janus Kinase/Signal Transducer and Activator of Transcription Pathway
KEGG	Kyoto Encyclopedia of Genes and Genomes
LAP TGF-beta-1	Latency-Associated Peptide of TGF-β1
LIF	Leukemia Inhibitory Factor
LIF-R	Leukemia Inhibitory Factor Receptor
MADRS	Montgomery–Åsberg Depression Rating Scale
MAPK	Mitogen-Activated Protein Kinase
MCP	Monocyte Chemotactic Protein
MCP-1	Monocyte Chemoattractant Protein 1 (CCL2)
MCP-2	Monocyte Chemoattractant Protein 2 (CCL8)
MCP-3	Monocyte Chemoattractant Protein 3 (CCL7)
MCP-4	Monocyte Chemoattractant Protein 4 (CCL13)
MDD	Major Depressive Disorder
MMP	Matrix Metalloproteinase (e.g., MMP-1)
MMP-1	Matrix Metallopeptidase 1
MMP-10	Matrix Metallopeptidase 10
MRI	Magnetic Resonance Imaging
NF-κB	Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
NPX	Normalized Protein Expression (Olink Platform Metric)

NRTN	Neurturin
NT-3	Neurotrophin-3
OPG	Osteoprotegerin (TNFRSF11B)
OSM	Oncostatin M
PD-L1	Programmed Death-Ligand 1 (CD274)
PEA	Proximity Extension Assay
pMADRS	Percentage Change in MADRS Item
RMT	Resting Motor Threshold
rTMS	Repetitive Transcranial Magnetic Stimulation
SCF	Stem Cell Factor (KITLG)
SCID-5-CV	Structured Clinical Interview for DSM-5 Disorders – Clinical Version
SD	Standard Deviation
SIRT2	Sirtuin 2
SLAMF1	SLAM Family Member 1
ST1A1	Sulfotransferase Family 1A Member 1
STAMBP	STAM Binding Protein
STAT3	Signal Transducer and Activator of Transcription 3
tENS	Transcutaneous Electrical Nerve Stimulation
TGF-alpha	Transforming Growth Factor Alpha
TNF	Tumor Necrosis Factor
TNF-α	Tumor Necrosis Factor Alpha
TNFB	Tumor Necrosis Factor Beta (Lymphotoxin Alpha)
TNFRSF9	TNF Receptor Superfamily Member 9 (4-1BB/CD137)
TNFSF14	TNF Superfamily Member 14 (LIGHT)
TRAIL	TNF-Related Apoptosis-Inducing Ligand (TNFSF10)
TRANCE	TNF-Related Activation-Induced Cytokine (RANKL/TNFSF11)
TSLP	Thymic Stromal Lymphopoietin
TWEAK	TNF-Like Weak Inducer of Apoptosis (TNFSF12)
uPA	Urokinase-type Plasminogen Activator
VEGFA	Vascular Endothelial Growth Factor A
WSS	Within-Cluster Sum of Squares
ΔMADRS	Change in MADRS Score (post-treatment minus baseline)

1. ABSTRACT

Background:
Major depressive disorder (MDD) is a disabling condition characterized by marked heterogeneity in treatment response. Inflammatory signaling pathways—such as cytokine–cytokine receptor interactions, JAK/STAT, and NF-κB activation—have been implicated in treatment resistance, particularly in severe depression. It remains unclear whether baseline inflammatory profiles can distinguish subgroups with variable outcomes following intermittent theta burst stimulation (iTBS), a non-invasive neuromodulatory treatment.

Methods:
In this exploratory study, we applied k-means clustering to baseline inflammatory protein expression data (Olink® Target 96 Inflammation panel) in patients with severe MDD undergoing iTBS. Clinical and general characteristics were compared across clusters. Differentially expressed proteins were identified using volcano plots with false discovery rate (FDR) correction. Kyoto Encyclopedia of Genes and Genomes and Reactome enrichment analyses identified biological pathways associated with each cluster.

Results:
Four inflammatory subgroups were identified. Cluster 1 had the highest proportion of treatment response; Cluster 4, the lowest. Clusters did not differ significantly by age, sex, medication, randomization, or BMI. Volcano plot analysis revealed 28 differentially expressed proteins (FDR < 0.05), with nine showing robust differences (e.g., IL-8, MCP-4, MMP-1, CXCL11, IL-7; |NPX difference| > 1). Enrichment analyses implicated cytokine-cytokine receptor interaction, chemokine signaling, and interleukin signaling pathways in the non-responders group.

Limitations:
Exploratory design, small sample size, and absence of a treatment control group are the main limitations. Lifestyle factors may have influenced immune markers.

Conclusions:
Baseline inflammatory profiles may differentiate iTBS treatment response in severe MDD, supporting immune-based stratification as a step toward personalized psychiatry.

2.   INTRODUCTION

Major depressive disorder (MDD) is a highly prevalent and disabling psychiatric condition, ranking among the leading causes of global disease burden (World Health Organization, 2017). Globally, it affects over 280 million people, with chronic and treatment-resistant forms accounting for up to one-third of cases (Rush et al., 2006).

Diagnostic classification systems such as the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) emphasize the importance of symptom severity in defining the clinical course of MDD. Severe depression is typically characterized by a higher number and intensity of symptoms, including suicidal ideation, somatic complaints, and pervasive feelings of guilt or worthlessness, all of which significantly impair social and occupational functioning (Zimmerman et al., 2018). This severe clinical presentation is associated with increased healthcare utilization, including more frequent emergency visits, hospitalizations, and an increased risk for long-term medical complications (Beiser et al., 2019; Chen and Lin, 2011; Voelker et al., 2021). Nevertheless, relying solely on global severity scores may overlook important heterogeneity within depression. Evidence from large-scale neuroimaging studies has suggested, for instance, that MDD may encompass multiple neurophysiological subtypes with distinct patterns of dysfunctional brain connectivity (Drysdale et al., 2017). These "biotypes" are not fully captured by clinical severity alone but are associated with specific symptom clusters and differential treatment responses, particularly to neuromodulation therapies. Although the findings of that study remain debated (Dinga et al., 2019), such work highlights the need for biologically informed classification approaches that extend beyond aggregate symptom counts to encompass underlying pathophysiological mechanisms.

Growing evidence suggests that immune system dysregulation plays a key role in the pathophysiology of MDD, particularly in its more severe or treatment-resistant forms. Elevated levels of inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and other chemokines have been repeatedly associated with increased symptom severity and poorer treatment outcomes (Gavril et al., 2024; Jeenger et al., 2017; Köhler-Forsberg et al., 2017; Orsolini et al., 2022; Paganin and Signorini, 2024). These markers often converge on pro-inflammatory signaling cascades such as Janus Kinase/Signal Transducer and Activator of Transcription Pathway (JAK/STAT) and Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB), which are known to influence neuroplasticity, monoaminergic transmission, and hypothalamic-pituitary-adrenal (HPA) axis regulation (Feng et al., 2024; Kennedy and Silver, 2016; Miller and Raison, 2016). Such findings have contributed to the recognition of a potential "inflammatory subtype" of depression (Raison and Miller, 2011; Schmidt et al., 2016; Strawbridge et al., 2019), particularly relevant in cases of chronic, recurrent, or resistant MDD.

In recent years, new non-pharmacological interventions such as repetitive transcranial magnetic stimulation (rTMS) have become established therapeutic options for individuals with MDD who do not respond adequately to antidepressant medication. Intermittent theta burst stimulation (iTBS), a variant of rTMS, has gained particular attention due to its shorter treatment sessions and comparable efficacy to standard 10 Hz protocols. By replicating endogenous theta rhythms associated with synaptic plasticity, iTBS modulates activity in key brain regions such as the left dorsolateral prefrontal cortex (DLPFC). iTBS has been approved by the U.S. Food and Drug Administration (FDA) for treatment-resistant unipolar depression and has shown promising

clinical results, with response rates varying from 20% to over 64%, depending on study design and patient characteristics (Blumberger et al., 2018; Cole et al., 2022; Lee et al., 2023; Neuteboom et al., 2023).

Despite its clinical potential, individual responses to rTMS and iTBS remain highly variable (Lefaucheur et al., 2014). Identifying reliable biomarkers to predict treatment outcomes is therefore essential for advancing personalized neuromodulation strategies (Breit et al., 2023). Peripheral cytokine levels have increasingly been associated with treatment outcomes in MDD, with specific markers such as TNF-α (Liu et al., 2020), IL-6 (Dahl et al., 2014; Yang et al., 2019) , and CRP (Uher et al., 2014) proposed as potential predictors of antidepressant response (Benedetti et al., 2021; Breit et al., 2023; Liu et al., 2020; Strawbridge et al., 2015). However, most studies on the relationship between inflammation and neuromodulation outcomes have focused on a limited number of cytokines, resulting in inconsistent findings (Pedraz-Petrozzi et al., 2024). For instance, a pilot study by Yilmaz and colleagues investigated inflammatory markers in patients with treatment-resistant depression undergoing rTMS, electroconvulsive therapy (ECT), or pharmacotherapy (Yilmaz et al., 2022). While higher baseline IL-6 and CRP levels were observed in non-responders, and rTMS was associated with reductions in TNF-α, the study was constrained by its small sample size and narrow biomarker scope. Thus, a broader and more comprehensive analysis of inflammatory pathways may help clarify these limitations and improve biomarker-based treatment stratification.

Advances in proteomic technologies now allow for the simultaneous measurement of a wide range of immune-related proteins in small biological samples (Assarsson et al., 2014). These methods provide a broader perspective on the immune landscape and have the potential to reveal complex biological patterns linked to treatment response (Lee et al., 2015). In psychiatric research, such multiplexed inflammatory profiling may improve our ability to stratify patients and personalize interventions (Fillman et al., 2014; Mesleh et al., 2021; Steiner et al., 2017; Yang et al., 2023).

To this end, the current exploratory study aimed to investigate baseline inflammatory profiles in patients with severe depression undergoing iTBS. Using a targeted proteomic approach, we investigated whether specific inflammatory signatures at baseline could distinguish between subgroups with variable treatment responses and provide insight into the biological mechanisms underlying these differences. Given the potential role of chronic low-grade inflammation in poor treatment outcomes in subgroups of MDD patients, this work sought to explore and contribute to the growing effort to integrate immunological markers into clinical outcomes. Finally, we hypothesized that distinct baseline immune-related protein expression patterns would differentiate patients with varying levels of symptom improvement following rTMS, reflecting underlying biological heterogeneity in treatment response

3. MATERIALS AND METHODS

3.1. Study design

This exploratory analysis is based on data derived from a larger clinical trial that investigated imaging, psychometric, and neuromodulatory outcomes associated with iTBS in patients with MDD (Name: Pre-mapping Networks for Brain Stimulation 2, clinicaltrials.gov/show/NCT05260086). The main study employed a six-week longitudinal design and has been previously described in detail elsewhere (Wilkening et al., 2022).

The trial followed a quadruple-blinded, randomized, sham-controlled, crossover design. Participants, care providers, investigators, and outcome raters were all blinded to treatment allocation. Each participant underwent two one-week stimulation phases—one with active iTBS and one with sham stimulation—with the order of administration (active-sham or sham-active) randomized across participants. Randomization was conducted using pre-coded sequences generated with a proper random number function in MATLAB (The MathWorks, Inc., Natick, MA, USA). The study was supervised by the principal investigator, who remained blinded to all participant interactions (Wilkening et al., 2022; Wilkening and Goya-Maldonado, 2025).

A parallel, pseudorandomized design was employed to investigate the clinical utility of individualized stimulation targeting. Participants were assigned to receive stimulation at a fixed scalp location (F3 according to the international 10–20 EEG system) or at a personalized site within the left DLPFC identified via resting-state functional MRI. For the present analysis, no distinction was made between fixed and personalized targeting, as the methods employed were similar in nature (Wilkening et al., 2022; Wilkening and Goya-Maldonado, 2025). Moreover, previous analyses of this cohort found no significant effect of stimulation target group on treatment outcome (Wilkening et al., 2025); so, the full sample was analyzed as a whole in the present study.

Symptom improvement was assessed using the Montgomery–Åsberg Depression Rating Scale (MADRS), administered by trained clinical interviewers at baseline and at the end of each week, enabling the evaluation of symptom change across the six-week study period (Wilkening et al., 2022; Wilkening and Goya-Maldonado, 2025).

3.2. Participants

The study protocol adhered to the Declaration of Helsinki and was approved by the Ethics Committee at the University Medical Center Göttingen (UMG). Prior to participation, all individuals gave both verbal and written informed consent after being thoroughly informed about the study procedures (Wilkening and Goya-Maldonado, 2025).

In the study protocol, eligible participants were adults between 18 and 60 years old who met the DSM-5 criteria for MDD and were in a moderate to severe depressive episode. This exploratory study included only those individuals with a baseline MADRS score of 20 or greater.

Trained psychiatrists confirmed the diagnosis through the Structured Clinical Interview for DSM-5 Disorders – Clinical Version (SCID-5-CV) and assessed depression severity using the MADRS (Hengartner et al., 2020; Montgomery and Åsberg, 1979; Wilkening and Goya-Maldonado, 2025). The study's exclusion criteria included any conditions that contraindicate rTMS, such as a history of epilepsy, significant neurological disorders, pregnancy, or having metallic implants (Wilkening and Goya-Maldonado, 2025).

For this exploratory study, we excluded participants showing laboratory signs of acute or systemic inflammation. This determination was based on routine laboratory measures, specifically CRP levels exceeding 10 mg/L or white blood cell counts above 11,000 cells/nL at baseline (leukocytosis) (Mank et al., 2025; Nehring et al., 2025).

Participants were required to adhere to a consistent psychopharmacological regimen for a minimum of two weeks prior to enrolling in the study and throughout the entire trial. Serum medication levels were frequently monitored to ensure compliance, and these measurements were included in the statistical model to account for possible confounding effects on clinical outcomes (Wilkening and Goya-Maldonado, 2025).

The study sample comprised both inpatients and outpatients; however, all neuromodulation sessions took place in an outpatient setting. Complete procedural information and the rationale behind the study have been previously published (Wilkening et al., 2025, 2022; Wilkening and Goya-Maldonado, 2025).

3.3. iTBS treatment

The technical specifications and implementation of the iTBS protocol used in this study have been described in detail elsewhere as part of the published study protocol (Wilkening et al., 2022; Wilkening and Goya-Maldonado, 2025). In summary, iTBS was administered using the MagVenture system with MagOption and a figure-of-eight MCF-B65 A/P cooled coil, operated by trained clinical personnel. Stimulation was delivered in four daily sessions, each lasting approximately 10 minutes and separated by at least 20-minute intervals, consistent with established inter-session spacing protocols (Tse et al., 2018; Wilkening and Goya-Maldonado, 2025). The stimulation paradigm followed a standard iTBS format: bursts of three pulses at 50 Hz delivered at 5 Hz, with 2 seconds of stimulation followed by 8 seconds of rest. Each session consisted of 60 bursts, totaling 1,800 pulses, resulting in 7,200 pulses per day and 36,000 pulses over the full course of treatment.

Resting motor threshold (RMT) was determined daily via electromyography of the right first dorsal interosseous muscle, defined as the minimum intensity required to elicit motor-evoked potentials ≥50 µV in 5 out of 10 consecutive trials. Stimulation was applied at 110% of RMT. For sham stimulation, the same coil was rotated 180 degrees to mimic the acoustic artifact without delivering effective stimulation. Additionally, transcutaneous electrical nerve stimulation (tENS) electrodes were applied to the scalp to replicate sensory experiences during both active and sham conditions. The efficacy of the blinding procedure was assessed using a visual analogue scale (Wilkening and Goya-Maldonado, 2025).

3.4. Proteomics: Inflammatory Marker Assessment and Enrichment Analysis

Peripheral venous blood samples were collected from all participants at baseline using ethylenediaminetetraacetic acid (EDTA) tubes. Baseline samples were obtained prior to allocation to groups (i.e., active-sham, sham-active). Plasma was separated by centrifugation at 3000 rpm for 15 minutes and stored at –80 °C in university research facilities for later analysis.

To assess a comprehensive panel of inflammatory markers, the Olink® Target 96 Inflammation panel (Olink Proteomics, Uppsala, Sweden) was utilized. This panel includes 92 inflammation-related proteins, quantified using proximity extension assay (PEA) technology. Each protein is detected using a pair of oligonucleotide-labeled antibodies. Upon binding to the target, the proximity of the antibodies enables DNA hybridization, which is subsequently amplified and

quantified via real-time PCR. The final data output is reported as Normalized Protein Expression (NPX) values, which are log2-transformed relative abundance units standardized by the manufacturer (Yang et al., 2023).

All Olink assays were performed at the Fraunhofer Institute for Translational Medicine and Pharmacology (Frankfurt am Main, Germany).

Following the identification of differentially expressed proteins (DEPs), pathway enrichment analyses were conducted to explore the biological context of the findings. Two complementary databases were utilized: the Kyoto Encyclopedia of Genes and Genomes (KEGG) for exploring genomic and pathway functions, and Reactome for mapping biological pathways and signaling mechanisms associated with the DEPs.

3.5. Statistical analysis

Initially, to identify potential subgroups based on baseline expression of inflammatory markers, we conducted a k-means cluster analysis. Prior to clustering, all NPX values were standardized to account for differences in scale across the 92 proteins, ensuring that each marker contributed equally to the clustering process.

Clustering was performed using the Hartigan–Wong algorithm, with a maximum of 1000 iterations to ensure convergence. To determine the number of clusters, we first applied the Elbow method (based on within-cluster sum of squares, WSS) to the standardized biomarker data. This method suggested a two-cluster solution, with the largest reduction in WSS (17.77%). However, given the exploratory aim of identifying subgroups based on their clinical response, we selected a four-cluster solution (k = 4). While a two-cluster solution minimized WSS, it offered limited clinical interpretability. The latter choice was also guided by clinical plausibility: specifically, the possibility of subgroups defined by the presence or absence of baseline inflammation and their subsequent response to treatment (i.e., response or non-response to treatment with low or high baseline inflammation). Similar frameworks were applied in other studies (Gloster et al., 2024; Martins et al., 2024). This clustering allowed for more granular stratification of treatment response based on immunologic profiles at baseline, which may reveal distinct pathophysiological or clinical subtypes. A graphical representation of inflammatory marker distributions across clusters is shown in **Figure 1**.

Figure 1 – Cluster profiles based on standardized inflammatory marker expression, generated using the Olink® Insight Stat Analysis Tool (Olink Proteomics, 2024). The y-axis represents the cluster profiles, and the x-axis shows the z-scores of the 92 inflammatory proteins included in the Olink panel in NPX. The plot illustrates the distinct inflammatory profiles of each cluster derived from k-means clustering.

To evaluate the clinical relevance of the clustering solution, we performed a one-way ANOVA on ΔMADRS (ΔMADRS = post-treatment minus baseline MADRS) to assess whether the resulting groups also differed significantly in treatment response, thereby providing empirical support for the clinical relevance of the chosen solution. This combined approach – grounded in a clinical rationale and supported by statistical differentiation – aligns with methods previously applied in other studies (e.g., Belanger et al., 2023). Thus, the four-cluster solution confirmed a balanced theoretical utility with observed clinical differentiation.

Once clusters were defined, we characterized each subgroup with respect to demographic (age, sex), anthropometric (body mass index), and medication variables. We also calculated the proportion of treatment responders—participants who achieved a ≥ 50% reduction in total MADRS score assessed post-treatment—and non-responders within each cluster. Continuous variables (age, BMI, and ΔMADRS) were compared across clusters using one-way ANOVA, followed by Tukey's honestly significant difference test for post-hoc pairwise comparisons, when the overall ANOVA reached $p < 0.05$. Categorical variables (sex distribution, medication classes, treatment resistance at baseline, randomization group, and responder percentages) were analyzed using chi-square tests.

Additionally, we explored changes in individual depression symptoms across the four inflammatory clusters using a network-based correlation analysis of percentage changes in MADRS item scores from pre- to post-iTBS. Items were grouped into symptom domains according to a validated factor structure (Borentain et al., 2022): anhedonic symptoms (items 1, 2, 7, 8), anxiety/vegetative symptoms (items 3-6), and hopelessness (items 9,10). This approach allowed us to explore inter-symptom dynamics within each immunologic profile. Within each cluster, Spearman correlations were computed between MADRS item changes to explore inter-symptom relationships. Significance was set at $p < 0.005$ (Bonferroni-corrected for 10 MADRS items).

For any pairwise cluster comparison that showed significant differences in symptom improvement (ΔMADRS), we conducted additional analyses of DEPs. For each protein, we calculated the mean NPX differences between the two clusters and conducted a volcano plot with Welch's t-tests. P-values were adjusted for multiple testing using the Benjamini-Hochberg FDR method. Proteins with FDR < 0.05 and an absolute NPX difference ≥ 1 (log2 scale) were considered significantly different and visualized in the volcano plots.

Finally, significantly DEPs were subsequently subjected to pathway enrichment analysis by using the KEGG and Reactome databases. Enrichment results were reported using q-values and FDR values, with statistical significance defined as q < 0.05 and FDR < 0.05.

All statistical analysis and visualizations, including enrichment analyses, were conducted in RStudio (version 2024.12.1+563). A heatmap of normalized protein expression values was generated using the Olink® Insight Stat Analysis Tool (Olink Proteomics, 2024).

4. RESULTS:

4.1. *Subgroup characterization: general characteristics, clinical outcomes and symptom interaction.*

Cluster Identification and Clinical Characterization

The k-means cluster analysis identified four distinct inflammatory subgroups (**Table 1**). Cluster 4 included the largest proportion of non-responders (16 out of 21 participants), whereas Cluster 1 had the highest proportion of responders (10 out of 14 participants). Clusters 2 and 3 exhibited mixed profiles regarding treatment response.

Following cluster determination, we characterized each group based on sociodemographic and clinical variables. No significant differences were observed across clusters in age ($F_{(3, 50)}$ = 0.510, p = 0.677), sex distribution (χ^2 = 1.595, df = 3, p = 0.677), or body mass index (BMI; $F_{(3, 39)}$ = 1.809, p = 0.161). Likewise, no significant group differences were found for treatment-related variables, including randomization order (sham-first vs. active-first), treatment resistance, or current medication regimen (all p > 0.05).

However, clusters differed significantly in symptom improvement, as measured by change in total MADRS scores from baseline to post-treatment (ΔMADRS; $F_{(3, 50)}$ = 4.122, p = 0.011). Tukey post hoc tests revealed significant differences between Cluster 1 and Cluster 4 (mean difference = -10.55; t = -3.10; p_{adj} = 0.016) and between Cluster 1 and Cluster 2 (mean difference = -11.33; t = -2.91; p_{adj} = 0.027). No significant differences were observed between Cluster 1 and Cluster 3 (p_{adj} = 0.722) or between Clusters 2 and 4 (p_{adj} = 0.997). The distribution of responders (defined as ≥50% reduction in MADRS score) also varied between clusters (χ^2 = 7.80, df = 3, p = 0.050), with Cluster 1 having the highest responder rate (71.43%) and Cluster 4 the lowest (23.81%). Finally, concerning the aforementioned clusters, a 2×2 chi-square analysis revealed no significant association between treatment order (sham-first vs. active-first) and response status (χ^2 = 0.486, df = 1, p = 0.486).

Symptom Network Analysis by Cluster

Distinct patterns of inter-symptom correlations emerged across the four inflammatory subgroups (**Figure 2**). In Cluster 1, strong positive correlations were observed between changes in suicidal thoughts (item 10), reported sadness (item 2), pessimistic thoughts (item 9), inability to feel (item 8), and reduced appetite (item 5) (all p < 0.005), suggesting a coordinated pattern of symptom improvement within this subgroup. Cluster 2 showed a generally weak inter-symptom association, except for a notable positive correlation between changes in reported sadness, apparent sadness (item 1), and concentration difficulties (item 6) (p < 0.005). In Cluster 3, moderate to strong correlations were found among "anhedonia" symptoms and between "hopelessness" items (p < 0.005), indicating a moderate co-occurrence of symptom changes. Lastly, Cluster 4 demonstrated positive correlations between percentage changes in apparent sadness, reported sadness, concentration difficulties, lassitude (item 7), inability to feel, and pessimistic thoughts (all p < 0.005), suggesting a potential interdependence between emotional symptom domains in this group.

For a detailed overview of the correlation coefficients and network visualizations, please refer to **Supplementary Material 1**.

Table 1. General and clinical characteristics of the four inflammatory clusters (derived from baseline inflammatory profiles), including statistical comparisons across groups. Data are presented as mean (SD) or counts. Group differences were assessed using one-way ANOVA (for continuous variables) or chi-squared tests (for categorical variables). Response was defined as ≥50% reduction in MADRS score from baseline. Marked in bold are p-values less than or equal to 0.05.

Abbreviations: BMI = body mass index, AD = antidepressants; MADRS = Montgomery–Åsberg Depression Rating Scale; SSRI = selective serotonin reuptake inhibitors.

Variable	Total (N = 54)	Cluster 1 (n = 14)	Cluster 2 (n = 12)	Cluster 3 (n = 7)	Cluster 4 (n = 21)	p-value	Test type
Age, years	34.50 (12.67)	33.21 (12.58)	31.83 (11.22)	33.86 (12.32)	37.10 (13.98)	0.677	One-Way ANOVA
Sex, female/male	26/28	5/9	7/5	3/4	11/10	0.061	Chi-squared
BMI, kg/m^2	25.70 (4.73)	26.29 (3.78)	22.98 (3.99)	27.65 (5.58)	26.61 (5.11)	0.161	One-Way ANOVA
Baseline MADRS	26.44 (5.03)	27.36 (5.81)	25.08 (4.38)	27.29 (5.06)	26.33 (4.98)		
Post-treatment MADRS	16.46 (9.52)	10.14 (6.49)	19.17 (10.13)	14.86 (10.54)	19.67 (8.90)		
ΔMADRS (post-baseline)	-9.98 (10.70)	-17.21 (9.21)	-5.92 (10.48)	-12.43 (10.29)	-6.67 (9.80)	**0.011**	One-Way ANOVA
Randomization order (active-sham/sham-active)						0.458	Chi-squared
Sham first	28	7	4	4	13		
Active first	26	7	8	3	8		
Treatment resistance						0.352	Chi-squared
Yes	18	3	5	4	6		
No	36	11	7	3	15		
Current medication						0.980	Chi-squared
No medication	19	5	4	3	7		
Medication, non-AD	3	1	1	0	1		
Other AD (non-SSRI)	18	6	3	2	7		
SSRI	14	2	4	2	6		
Response (MADRS ≥ 50%)						**0.050**	Chi-squared
Responders	23	10	5	3	5		
Non-responders	31	4	7	4	16		

Figure 2 - Correlation network analysis of the Montgomery-Åsberg Depression Rating Scale (MADRS) items was conducted for each immunological cluster using percentual changes. Edges are colored and weighted based on statistical significance: correlations with p-values greater than 0.05 are depicted in light gray; those with p-values between 0.005 and 0.05 are shown in light blue or light red; and strong blue or red colors represent correlations with p-values less than or equal to 0.005. Abbreviations: pMADRS, percentual change of MADRS item; MADRS1, apparent sadness; MADRS2, reported sadness; MADRS3, inner tension; MADRS4, reduced sleep; MADRS5, reduced appetite; MADRS6, concentration difficulties; MADRS7, lassitude; MADRS8, inability to feel; MADRS9, pessimistic thoughts; MADRS10, suicidal thoughts.

4.2. Inflammatory parameters - differences between cluster 4 and 1

After observing differences in symptom improvement between cluster 4 and cluster 1, we investigated the disparities in inflammatory parameters between these two groups. These clusters represent opposite extremes in our sample — cluster 1 includes, for instance, the highest proportion of responders, while cluster 4 contains the highest proportion of non-responders. To achieve this, we created a volcano plot utilizing the NPX values, which were adjusted for multiple comparisons through the FDR. A parameter was deemed significant if it satisfied two conditions: an FDR less than 0.05 and an absolute NPX difference exceeding 1.

Out of the 92 inflammatory parameters analyzed, 28 showed an FDR < 0.05 (namely, MCP4, CXCL6, IL7, CXCL1, OSM, CXCL5, IL8, MCP1, VEGFA, CXCL11, LAP TGF beta 1, Beta NGF, HGF, CCL4, IL2, MMP1, CCL11, FGF23, CSF1, LIFR, TNFSF14, TSLP, CD40, CCL28, MCP3, TGF alpha, TWEAK, IL6; see **Supplementary Material 2** for the FDR p-adjusted values). However, only 9 of these parameters met both significance criteria, showing an FDR < 0.05 and an absolute NPX difference greater than 1; these were MCP4, CXCL6, IL7, CXCL1, OSM, CXCL5, IL8, CXCL11, MMP1 (**Supplementary Material 2** details the FDR-adjusted p-values and NPX differences for these markers). **Figure 3** illustrates the volcano plot, while **Figure 4** displays box plots for these nine significant parameters, highlighting the differences in expression between cluster 4 and cluster 1.

Figure 3 - Volcano plot of NPX differences between cluster 4 and cluster 1. Vertical blue dotted lines denote NPX differences of +1 and −1. The horizontal red dashed line indicates the FDR-adjusted p-value threshold of 0.05. Abbreviations: NPX = Normalized Protein Expression; IL-7 = Interleukin-7; IL-8 = Interleukin-8; CXCL11 = C-X-C motif chemokine ligand 11; CXCL1 = C-X-C motif chemokine ligand 1; OSM = Oncostatin M; MMP-1 = Matrix metalloproteinase-1; CXCL6 = C-X-C motif chemokine ligand 6; MCP-4 = Monocyte chemotactic protein-4; CXCL5 = C-X-C motif chemokine ligand 5.

Figure 4 - Boxplots of baseline NPX values for nine significantly different inflammatory proteins between cluster 1 and cluster 4. Clusters correspond to patient subgroups with the highest (Cluster 1) versus the lowest (Cluster 4) iTBS response rates; FDR-adjusted p-values are indicated above each plot. Abbreviations: NPX = Normalized Protein Expression; IL-7 = Interleukin-7; IL-8 = Interleukin-8; CXCL11 = C-X-C motif chemokine ligand 11; CXCL1 = C-X-C motif chemokine ligand 1; OSM = Oncostatin M; MMP-1 = Matrix metalloproteinase-1; CXCL6 = C-X-C motif chemokine ligand 6; MCP-4 = Monocyte chemotactic protein-4; CXCL5 = C-X-C motif chemokine ligand 5.

4.3. Inflammatory parameters - differences between cluster 2 and 1

We also analyzed the differences between cluster 2 and cluster 1, as both groups demonstrated variations in symptom improvement. However, compared to cluster 4 and cluster 1, we found no significant differences in inflammatory parameters between cluster 2 and cluster 1 (see **Supplementary Material 3** for details).

4.4. Enrichment analysis:

To investigate the roles of the nine baseline DEPs, we performed KEGG and Reactome enrichment analyses. The KEGG pathway enrichment analysis revealed several significantly enriched pathways, including the cytokine–cytokine receptor interaction pathway (**Figure 5**). This pathway, which is critical for cellular responses to stress and inflammation, was highly enriched in our dataset (FDR = 6.62e-10, q = 3.48e-10). Similarly, immune signaling pathways—such as the viral protein interaction with cytokine and cytokine receptor pathway (**Figure 5**)—were significantly enriched (FDR = 3.43e-09, q = 1.80e-09). Additionally, the rheumatoid arthritis pathway (**Figure 5**) was enriched (FDR = 1.41e-07, q = 7.43e-08), suggesting a potential role in mediating immune and inflammatory responses. These findings indicate a strong involvement of

immune signaling pathways in the response to rTMS treatment. Additional results from the KEGG enrichment analysis are summarized in **Supplementary Material 4**.

Figure 5 - Results of KEGG pathway enrichment analysis. The x-axis represents the GeneRatio (i.e., the proportion of genes in each pathway that overlap with the list of differentially expressed proteins). Bubble size corresponds to the number of overlapping genes, while color indicates the adjusted p-value.

Reactome pathway enrichment analysis was performed to elucidate the biological processes associated with the DEPs between cluster 4 and cluster 1. The analysis revealed significant enrichment of pathways related to chemokine and cytokine receptor signaling and receptor-mediated events. Notably, the "Chemokine receptors bind chemokines" pathway was the most enriched, with 6 of 9 proteins participating (FDR = 3.37e-11, q = 1.33e-11). Other highly enriched pathways include "Peptide ligand-binding receptors" (FDR = 3.08e-08, q = 1.21e-08) and "G alpha (i) signaling events" (FDR = 3.22e-07, q = 1.27e-07). Additionally, the enrichment of the "Class A/1 (Rhodopsin-like receptors)" pathway (FDR = 3.24e-07, q = 1.28e-07) supports the involvement of GPCRs in the observed responses. Several interleukins signaling cascades, including "Interleukin-4 and Interleukin-13 signaling" (FDR = 2.44e-04, q = 9.64e-05) and "Interleukin-10 signaling" (FDR = 1.84e-03, q = 7.28e-04). Overall, these findings indicate that DEPs between cluster 4 and cluster 1 are predominantly associated with immune-related receptor signaling and stress-response pathways, which may be critical for understanding the response to rTMS (**Figure 6**). Detailed enrichment results are provided in **Supplementary Material 4**.

Figure 6 – Tree plot visualization of Reactome pathway enrichment analysis results. The plot illustrates various biological pathways, with node size reflecting the significance of enrichment and color indicating enrichment scores. For detailed methodological information, please refer to Supplementary Material 4.

5. DISCUSSION

Our findings demonstrated that k-means clustering identified four distinct molecular subgroups based on inflammatory biomarker profiles. Cluster 1 exhibited the highest proportion of treatment responders, while Cluster 4 included the greatest number of non-responders. Despite significant differences in symptom improvement across clusters, no significant group differences were observed in age, sex, medication group, randomization, or BMI, indicating that the clustering was primarily driven by the immune markers. In addition, symptom network analysis further revealed distinct inter-symptom dynamics across the subgroups. Cluster 1, which also corresponded to high treatment response, showed coordinated improvements in anhedonia, hopelessness, and vegetative symptoms. Cluster 2 showed limited interconnections, primarily involving sadness and concentration difficulties. Cluster 3 displayed co-occurring changes in anhedonia and hopelessness. Cluster 4 showed correlations among anhedonia, cognitive, and hopelessness despite low response. These patterns may indicate distinct symptom dynamics associated with different inflammatory profiles.

A direct comparison between Clusters 1 and 4—representing the extremes of treatment response—identified nine proteins (MCP-4, CXCL6, IL-7, CXCL1, OSM, CXCL5, IL-8, CXCL11, and MMP-1) with significant expression differences (FDR < 0.05; |ΔNPX| > 1), as visualized in a volcano plot. Pathway enrichment analyses using KEGG and Reactome databases indicated that these proteins are primarily involved in immune-related signaling cascades, including chemokine and cytokine receptor interactions, GPCR signaling, interleukin signaling, and cellular stress responses. Together, these results suggest the presence of a baseline inflammatory molecular signature that differentiates patients with varying iTBS treatment outcomes in severe depression.

5.1. *Cluster Differences and the Role of Baseline Inflammation in Clinical Outcomes*

In this exploratory study, we identified four distinct patient subgroups based on their baseline inflammatory profiles, which differed according to clinical outcomes following iTBS treatment. Importantly, these differences in clinical response were not explained by age, sex, or BMI, supporting the view that the clustering reflects underlying biological mechanisms rather than demographic confounders. Concerning the inter-symptom dynamics among clusters, Cluster 1 showed the highest proportion of treatment responders and exhibited coordinated improvements across anhedonia and hopelessness domains, and reduced appetite (vegetative symptom). In contrast, Cluster 4 included the highest proportion of non-responders and showed correlated changes across a broader range of symptoms, including sadness, pessimism, concentration difficulties, and lassitude. Clusters 2 and 3 demonstrated intermediate patterns, with Cluster 2 showing limited symptom interconnections and Cluster 3 reflecting co-occurring changes in anhedonia and hopelessness domains.

To our knowledge, this is the first report that shows inflammatory heterogeneous profiles in depression patients undergoing iTBS treatment. Nevertheless, this observation is consistent with growing evidence linking inflammation to both the pathophysiology and treatment outcomes of MDD, especially in a subgroup of patients. While depression is not universally characterized by inflammation, a distinct subset of patients appears to exhibit a proinflammatory state, often marked by elevated levels of cytokines such as IL-6, TNF-α, and CRP (Miller and Raison, 2016; Schmidt et al., 2016). For instance, up to 45% of patients with antidepressant treatment

resistance show elevated CRP levels, suggesting that systemic inflammation may contribute to reduced treatment efficacy (Miller and Raison, 2016).

Furthermore, prior studies have demonstrated that baseline cytokine levels can predict response to antidepressant treatment, with higher levels of proinflammatory markers associated with poorer outcomes (Gadad et al., 2017; Strawbridge et al., 2015; Uher et al., 2014). For example, Uher and colleagues found that CRP could differentially predict response to escitalopram versus nortriptyline, while O'Brien and colleagues reported elevated TNF-α and IL-6 in treatment-resistant patients (O'Brien et al., 2007; Uher et al., 2014). Similarly, Schmidt and colleagues proposed the existence of an inflammatory cytokine-associated depressive subtype (Schmidt et al., 2016).

While some inflammatory markers, such as CRP or IL-6, remain one of the most commonly used inflammatory markers in clinical and research settings, their value in depression as a therapeutic marker is limited by their lack of specificity. This underscores the broader heterogeneity of inflammatory states in depression and emphasizes the need for more refined and multi-parametric immune profiling approaches (Jha and Trivedi, 2018).

These findings reinforce the hypothesis that not all individuals with depression exhibit the same underlying biology and that inflammation may serve as a mechanistic bridge between depressive symptoms and treatment resistance. While most depressed patients have cytokine levels within the normal range (Raison and Miller, 2011), a meaningful subset shows immune dysregulation that may actively interfere with treatment response—a pattern supported by our identification of inflammatory clustering.

Taken together, these results suggest that baseline immune profiling could enhance treatment stratification in clinical settings and may help guide personalized therapeutic approaches, particularly for non-responders to interventions, in our case iTBS.

5.2. Inflammatory Profile Differences and Pathway Enrichment

Analysis of baseline inflammatory profiles revealed distinct immune signatures between patients with divergent responses to iTBS treatment. A volcano plot comparing inflammatory marker expression between Cluster 4 (predominantly non-responders) and Cluster 1 (predominantly responders) identified 28 out of 92 proteins as significantly differentially expressed (FDR < 0.05). Among these, nine markers—MCP4, CXCL6, IL7, CXCL1, OSM, CXCL5, IL8, CXCL11, and MMP1—met more stringent criteria, demonstrating both an FDR below 0.05 and an absolute NPX difference greater than 1. These findings highlight the presence of distinct baseline inflammatory profiles between patients with favorable and unfavorable clinical outcomes.

Interestingly, although Cluster 4 had a higher percentage of sham-first participants, our analysis did not find a significant relationship between treatment order and clinical response. This suggests that the differences in treatment outcomes between clusters 4 and 1 are unlikely to be due to the order of treatment (sham or active first).

Furthermore, pathway enrichment analyses were performed to explore the biological relevance of these DEPs further. KEGG enrichment analysis revealed a prominent involvement of immune-related signaling pathways, mainly cytokine–cytokine receptor interaction. Complementary Reactome enrichment analysis supported these findings, showing significant enrichment in chemokine and cytokine receptor signaling, interleukin signaling cascades, and cellular stress response mechanisms. Collectively, these results suggest that baseline immune

dysregulation—particularly in cytokine signaling and chemotactic activity—may be mechanistically linked to differential response patterns following iTBS treatment in patients with depression.

5.2.1.   Interleukin signaling:

Initially, our findings revealed notable baseline differences in immune parameters associated with interleukin signaling and cytokine-cytokine receptor interactions (such as CXCLs, MCP-4, OSM, IL-8, IL-7) between Clusters 4 and 1, which showed different treatment response patterns during iTBS therapy.

Among the markers observed, IL-8 plays a pivotal role in the recruitment of neutrophils to sites of infection and tissue damage (Yoshimura et al., 1987). Additionally, the monocyte chemotactic protein (MCP) family, including CCL2, CCL7, CCL8, CCL12, and CCL13 (designated as MCP1-5), exerts potent pro-inflammatory actions through the chemotaxis of monocyte-derived macrophages and other inflammatory leukocytes to the inflamed or injured central nervous system (CNS) (Stuart et al., 2015). Oncostatin M (OSM), a member of the IL-6 cytokine family, activates the JAK/STAT signaling pathway via the OSM receptor and gp130 (Han et al., 2023). This pathway is critical for regulating inflammation and tissue repair. IL-7, a classic cytokine in the interleukin signaling pathway, is primarily involved in T cell development and homeostasis (Chen et al., 2021). Furthermore, the CXC chemokine family—which includes CXCL1, CXCL5, CXCL6, and CXCL11—comprises cytokines involved in inflammatory processes and may be part of downstream interleukin signaling networks, contributing to immune cell recruitment and activation during inflammation (Milenkovic et al., 2019; Stuart et al., 2015).

In the context of MDD, cytokines appear to contribute not only to the onset and progression of the affective disorder but also to variability in treatment response (Liu et al., 2020). Notably, Syed and colleagues reported that patients who responded to antidepressant treatment exhibited stabilization of pro-inflammatory cytokine levels, whereas non-responders showed persistent or increasing inflammatory activity over the course of treatment (Syed et al., 2018). Increasing evidence suggests that markers related to interleukin signaling play a central role in the pathophysiology of MDD and may significantly influence treatment efficacy. Several studies have demonstrated associations between baseline inflammatory markers—particularly interleukins and chemokines—and antidepressant outcomes. For example, a meta-analysis by Liu and colleagues found that patients who responded to treatment had significantly lower baseline IL-8 levels compared to non-responders, and that TNF-α levels decreased significantly only among responders (Liu et al., 2020). In line with these findings, multiple studies have reported that elevated IL-8 and IL-6 levels are associated with poorer treatment outcomes, further implicating this chemokine as a potential biomarker of antidepressant resistance (Fonseka et al., 2015; Gasparini et al., 2022; Guan et al., 2022). Other chemokines have also shown relevance. For instance, CXCL11 (interferon-inducible T-cell alpha chemoattractant or ITAC) has been linked to antidepressant response, with Lan and colleagues demonstrating that lower baseline levels predicted more favorable outcomes in both first-episode MDD and treatment-resistant depression treated with ketamine (Lan et al., 2021).

Taken together, these findings suggest that elevated baseline levels of signaling interleukins may help differentiate patients with poorer treatment response in MDD. This supports the hypothesis that a pre-existing inflammatory state contributes to variability in treatment outcomes, underscoring the potential value of stratified interventions targeting immune-related pathways.

5.2.2. Oncostatin M:

OSM is a multifunctional cytokine within the IL-6 family, structurally related to leukemia inhibitory factor (LIF) (Knight, 2022; Tanaka and Miyajima, 2003). It is primarily secreted by activated T lymphocytes and macrophages and exerts a wide range of context-dependent biological effects, including pro- and anti-inflammatory activity, hematopoietic regulation, and tumor growth inhibition (Richards, 2013). OSM activates key intracellular signaling cascades such as the JAK/STAT and MAPK pathways, influencing cell proliferation, inflammation, and immune responses (Han et al., 2023).

In vivo, OSM induces acute inflammatory reactions by promoting leukocyte transmigration and adhesion, mediated via endothelial cell activation, and enhances the expression of adhesion molecules and pro-inflammatory cytokines (Modur et al., 1997). It has been implicated in several chronic inflammatory and autoimmune diseases, including rheumatoid arthritis, pulmonary and dermatologic inflammation, and cardiovascular conditions, highlighting its potential as a therapeutic target (Han et al., 2023; Richards, 2013).

Despite its immunological relevance, no studies have specifically examined OSM concerning treatment response in depression. Our study is, therefore, the first to report baseline differences of OSM in groups with variable response proportions. However, Franzen and colleagues were the first to identify OSM, IL-6, and STAT3 as key upstream regulators of pro-inflammatory signaling in cerebrospinal fluid from individuals with depression (Franzen et al., 2020). These molecules were associated with acute phase response signaling, a pathway frequently implicated in mood disorders (Franzen et al., 2020). While IL-6 and STAT3 have been linked to serotonin transporter regulation and depression-like behaviors, OSM has not yet been investigated in clinical studies, despite its close mechanistic relationship, remaining unexplored despite their evident involvement in relevant signaling pathways (Franzen et al., 2020).

5.2.3. Matrix Metalloproteinase 1 (MMP-1):

An interesting and unreported finding from our study was the elevated baseline levels of MMP-1 in the cluster of individuals showing the lowest response to iTBS. To our knowledge, this is the first report in depression research describing increased MMP-1 levels in non-responders, suggesting a potential role for this enzyme in modulating treatment outcomes. MMP-1 is primarily involved in the breakdown of interstitial collagens and is a key mediator of tissue remodeling and repair. Its expression is typically induced under conditions of physiological stress, such as wound healing, inflammation, or fibrotic remodeling (Pardo and Selman, 2005). MMP-1 has also been implicated in a range of inflammatory and degenerative diseases, including cancer, rheumatoid arthritis, pulmonary emphysema, and fibrotic disorders (Pardo and Selman, 2005). Accumulating evidence suggests that matrix metalloproteinases (MMPs) play a significant role in depression; however, the evidence in this matter is contradictory. On the one hand, one study reported elevated serum levels of MMP-2 and MMP-9 in people with depression when compared to healthy controls, indicating a potential link between extracellular matrix remodeling and depressive pathology. In contrast, levels of tissue inhibitor of metalloproteinase-1 (TIMP-1)—a natural inhibitor of MMP-1—have been reported to be higher in control groups, suggesting a possible imbalance between MMP activity and its regulation in depression (Hamed et al., 2020). On the other hand, an intervention study found that serum MMP-2 levels were lower prior to ECT in patients with depression but increased significantly following treatment, while MMP-9 levels

decreased. These changes were associated with specific depressive symptom profiles (Shibasaki et al., 2016).

In contrast to findings from ECT studies, where reduced MMP-2 levels were observed in patients with depression prior to treatment (Shibasaki et al., 2016), our results revealed elevated baseline MMP-1 levels in the cluster of participants with a higher proportion of non-responders to iTBS. This discrepancy suggests that treatment response may vary depending on the type of intervention, potentially reflecting differences in the substrate specificity and biological functions of the respective MMPs.

Taken together, these findings raise the possibility that matrix remodeling enzymes may play a critical role in the relationship between immune dysfunction and treatment response in severe depression, warranting further investigation.

5.3. *Strengths*:

This study has two main strengths. First, despite its exploratory approach, it employs a clustering approach to identify biologically distinct subgroups among patients with severe depression undergoing iTBS. This method moves beyond traditional clinical classification and reveals molecular heterogeneity at baseline that may underlie variable treatment outcomes. Second, by integrating baseline inflammatory profiling with treatment response data, the study uncovers differential expression of key immune-related proteins and their enrichment in biologically meaningful pathways, such as cytokine–cytokine receptor interactions or interleukin signaling, offering mechanistic insight into the role of immune dysregulation in depression.

Overall, the combination of distinct molecular subgroups, differential inflammatory profiles at baseline, and enriched immune signaling pathways strongly suggests that immune regulation may play a central role in mediating variable response to iTBS treatment, offering a valuable foundation for future research and biomarker-guided therapeutic strategies.

5.4. *Limitations*:

However, this study has several limitations that should be acknowledged. First, its exploratory design limits the ability to draw causal inferences between inflammatory markers and treatment response. The findings should therefore be considered hypothesis-generating and require confirmation in future longitudinal and interventional studies.

Second, the analysis was based solely on baseline protein expression, without assessing changes in inflammatory profiles over time. Including post-treatment data would provide a more dynamic picture of how immune markers evolve in response to iTBS. Additionally, the absence of a control group or alternative treatment arms (e.g., pharmacotherapy or ECT) limits the ability to determine whether the observed immune patterns are specific to rTMS/iTBS or reflect general features of treatment response.

Third, while the study used a high-sensitivity proteomic panel, the Olink Inflammation panel is limited to a preselected set of immune-related proteins. This inherently biases pathway enrichment analyses toward immune processes and may overlook other biologically relevant pathways. Moreover, the number of DEPs driving the enrichment analyses was relatively small, which constrains the robustness and interpretability of the identified pathways.

Fourth, potential confounding factors—such as prior medication use, lifestyle variables (e.g., diet, smoking), and socioeconomic or psychosocial stressors—may have influenced cytokine

levels. While clinical history was considered, more controlled designs or treatment-naïve samples are needed to clarify the specific role of inflammation in depression.

Fifth, the sample consisted exclusively of individuals with severe depressive episodes, potentially limiting generalizability to broader populations. Including patients with varying symptom severity in future studies could help determine whether inflammatory differences are specific to severe forms of depression.

Finally, due to the limited sample size and the exploratory nature of the study, more complex analyses—such as detailed associations between specific symptom dimensions and protein levels—were not conducted, as they also lay beyond the primary scope of the research. These aspects warrant further investigation in larger, confirmatory studies.

5.5.   *Future perspectives and hypotheses*:

Building on our exploratory findings, several hypotheses can guide future research into the immunological mechanisms underlying treatment response in depression, particularly in the context of iTBS. The identification of molecular subgroups based on inflammatory profiles—highlighted by differential expression of proteins such as IL-8, CXCL1, CXCL11, MMP-1, and OSM—suggests that biologically distinct inflammatory subtypes may contribute to variability in treatment outcomes. Unsupervised clustering in larger cohorts could help delineate these subgroups more precisely, supporting a personalized approach to intervention.

Future studies should examine whether pathways involving OSM and IL-6/JAK/STAT signaling are mechanistically linked to treatment response, across both neuromodulatory and pharmacological therapies. Longitudinal designs assessing changes in inflammatory markers before and after treatment are needed to evaluate the predictive utility of baseline immune profiles, particularly in identifying non-responders.

Our findings also implicate chemokines and matrix remodeling enzymes (e.g., CXCL and MMP families) as potential biomarkers of poor treatment response in patients with high baseline inflammation. Notably, the elevated inflammatory signatures and low response rates observed in Cluster 4 may reflect an immune-resistant depression subtype. This raises the possibility that such patients might benefit from iTBS augmentation with a specific immunomodulatory drug (e.g., anti-inflammatory agents) or targeted pharmacological interventions addressing inflammatory dysregulation.

Lastly, future work should investigate the relationship between peripheral inflammation and neural circuit dysfunction or white-matter abnormalities, which may elucidate how immune signaling influences brain function and iTBS responsiveness in depression.

Lastly, future research should explore the relationship between peripheral inflammation and neural circuit dysfunction or white-matter abnormalities to better understand how immune signaling influences brain function and iTBS responsiveness in depression. Comparative studies involving other treatment modalities—such as ECT or pharmacotherapy—may further clarify whether these immune-related mechanisms are specific to rTMS or generalizable across interventions.

6.   CONCLUSIONS

In conclusion, this exploratory study showed that distinct inflammatory profiles at baseline could be used to identify biologically subgroups of patients with severe depression who exhibit differential clinical responses to iTBS treatment. Specifically in the context of our study, patients

within Cluster 4, characterized by higher expression of cytokine-related and chemotactic markers, showed poorer treatment outcomes, suggesting a more immune-dysregulated and pro-inflammatory state. Conversely, Cluster 1, which included the highest proportion of treatment responders, displayed a less inflammatory profile, indicating that a reduced immune-active environment may be more favorable for iTBS response.

Cytokines—small signaling proteins—are known to regulate essential cellular processes such as proliferation, apoptosis, and immune activation (Voßhenrich and Santo, 2002). In this context, our findings suggest that patients with elevated baseline activity in cytokine signaling and cytokine–cytokine receptor interaction pathways may be less likely to respond to neuromodulatory treatments like iTBS, potentially due to a persistently activated inflammatory state that impairs therapeutic efficacy.

Given the exploratory nature of this study, the findings should be interpreted with caution and considered primarily as hypothesis-generating. However, the findings offer important insights that may inform future efforts to develop immune-based treatment strategies and biologically informed patient stratification in depression, particularly in relation to neuromodulatory interventions such as iTBS. Further prospective, longitudinal, and mechanistic studies are warranted to validate these associations and to elucidate the potential causal role of immune dysregulation in mediating variability in treatment outcomes.

7.   BIBLIOGRAPHY

Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Thorsen, S.B., Ekman, D., Eriksson, A., Dickens, E.R., Ohlsson, S., Edfeldt, G., Andersson, A.-C., Lindstedt, P., Stenvang, J., Gullberg, M., Fredriksson, S., 2014. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability. PLOS ONE 9, e95192. https://doi.org/10.1371/journal.pone.0095192

Beiser, D.G., Ward, C.E., Vu, M., Laiteerapong, N., Gibbons, R.D., 2019. Depression in Emergency Department Patients and Association With Health Care Utilization. Acad. Emerg. Med. 26, 878–888. https://doi.org/10.1111/acem.13726

Belanger, H.G., Lee, C., Winsberg, M., 2023. Symptom clustering of major depression in a national telehealth sample. J. Affect. Disord. 338, 129–134. https://doi.org/10.1016/j.jad.2023.05.026

Benedetti, F., Poletti, S., Vai, B., Mazza, M.G., Lorenzi, C., Brioschi, S., Aggio, V., Branchi, I., Colombo, C., Furlan, R., Zanardi, R., 2021. Higher baseline interleukin-1β and TNF-α hamper antidepressant response in major depressive disorder. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 42, 35–44. https://doi.org/10.1016/j.euroneuro.2020.11.009

Blumberger, D.M., Vila-Rodriguez, F., Thorpe, K.E., Feffer, K., Noda, Y., Giacobbe, P., Knyahnytska, Y., Kennedy, S.H., Lam, R.W., Daskalakis, Z.J., Downar, J., 2018. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet 391, 1683–1692. https://doi.org/10.1016/S0140-6736(18)30295-2

Borentain, S., Gogate, J., Williamson, D., Carmody, T., Trivedi, M., Jamieson, C., Cabrera, P., Popova, V., Wajs, E., DiBernardo, A., Daly, E.J., 2022. Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. Int. J. Methods Psychiatr. Res. 31, e1927. https://doi.org/10.1002/mpr.1927

Breit, S., Mazza, E., Poletti, S., Benedetti, F., 2023. White matter integrity and pro-inflammatory cytokines as predictors of antidepressant response in MDD. J. Psychiatr. Res. 159, 22–32. https://doi.org/10.1016/j.jpsychires.2022.12.009

Chen, X., Wu, R., Xu, J., Wang, J., Gao, M., Chen, Y., Pan, Y., Ji, H., Duan, Y., Sun, M., Du, L., Zhou, L., 2021. Prevalence and associated factors of psychological distress in tuberculosis patients in Northeast China: a cross-sectional study. BMC Infect. Dis. 21, 563. https://doi.org/10.1186/s12879-021-06284-4

Chen, Y.-H., Lin, H.-C., 2011. Increased risk of cancer subsequent to severe depression--a nationwide population-based study. J. Affect. Disord. 131, 200–206. https://doi.org/10.1016/j.jad.2010.12.006

Cole, E.J., Phillips, A.L., Bentzley, B.S., Stimpson, K.H., Nejad, R., Barmak, F., Veerapal, C., Khan, N., Cherian, K., Felber, E., Brown, R., Choi, E., King, S., Pankow, H., Bishop, J.H., Azeez, A.,

Coetzee, J., Rapier, R., Odenwald, N., Carreon, D., Hawkins, J., Chang, M., Keller, J., Raj, K., DeBattista, C., Jo, B., Espil, F.M., Schatzberg, A.F., Sudheimer, K.D., Williams, N.R., 2022. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am. J. Psychiatry 179, 132–141. https://doi.org/10.1176/appi.ajp.2021.20101429

Dahl, J., Ormstad, H., Aass, H.C.D., Malt, U.F., Bendz, L.T., Sandvik, L., Brundin, L., Andreassen, O.A., 2014. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 45, 77–86. https://doi.org/10.1016/j.psyneuen.2014.03.019

Dinga, R., Schmaal, L., Penninx, B.W.J.H., van Tol, M.J., Veltman, D.J., van Velzen, L., Mennes, M., van der Wee, N.J.A., Marquand, A.F., 2019. Evaluating the evidence for biotypes of depression: Methodological replication and extension of. NeuroImage Clin. 22, 101796. https://doi.org/10.1016/j.nicl.2019.101796

Drysdale, A.T., Grosenick, L., Downar, J., Dunlop, K., Mansouri, F., Meng, Y., Fetcho, R.N., Zebley, B., Oathes, D.J., Etkin, A., Schatzberg, A.F., Sudheimer, K., Keller, J., Mayberg, H.S., Gunning, F.M., Alexopoulos, G.S., Fox, M.D., Pascual-Leone, A., Voss, H.U., Casey, B.J., Dubin, M.J., Liston, C., 2017. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat. Med. 23, 28–38. https://doi.org/10.1038/nm.4246

Feng, X., Ma, X., Li, J., Zhou, Q., Liu, Y., Song, J., Liu, J., Situ, Q., Wang, L., Zhang, J., Lin, F., 2024. Inflammatory Pathogenesis of Post-stroke Depression. Aging Dis. 16, 209–238. https://doi.org/10.14336/AD.2024.0203

Fillman, S.G., Sinclair, D., Fung, S.J., Webster, M.J., Shannon Weickert, C., 2014. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl. Psychiatry 4, e365. https://doi.org/10.1038/tp.2014.8

Fonseka, T.M., McIntyre ,Roger S, Soczynska ,Joanna K, and Kennedy, S.H., 2015. Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opin. Investig. Drugs 24, 459–475. https://doi.org/10.1517/13543784.2014.998334

Franzen, A.D., Lam, T.T., Williams, K.R., Nairn, A.C., Duman, R.S., Sathyanesan, M., Kumar, V., Carpenter, L.L., Newton, S.S., 2020. Cerebrospinal fluid proteome evaluation in major depressive disorder by mass spectrometry. BMC Psychiatry 20, 481. https://doi.org/10.1186/s12888-020-02874-9

Gadad, B.S., Jha, M.K., Grannemann, B.D., Mayes, T.L., Trivedi, M.H., 2017. Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial. J. Psychiatr. Res. 94, 1–6. https://doi.org/10.1016/j.jpsychires.2017.05.012

Gasparini, A., Callegari, C., Lucca, G., Bellini, A., Caselli, I., Ielmini, M., 2022. Inflammatory Biomarker and Response to Antidepressant in Major Depressive Disorder: a Systematic Review and Meta-Analysis. Psychopharmacol. Bull. 52, 36–52.

Gavril, Radu, Dobrin, P.R., Pînzariu, A.C., Moscalu, M., Grigore, R.G., Iacob, V.T., Bejenariu, A.C., Popescu, E.R., Gavril, Raluca, Gireadă, B., Soroceanu, R.P., Gavrilovici, O., Ştefănescu, C., 2024. Predictive Value of Inflammatory Biomarkers in Assessing Major Depression in Adults. Biomedicines 12, 2501. https://doi.org/10.3390/biomedicines12112501

Gloster, A.T., Nadler, M., Block, V., Haller, E., Rubel, J., Benoy, C., Villanueva, J., Bader, K., Walter, M., Lang, U., Hofmann, S.G., Ciarrochi, J., Hayes, S.C., 2024. When Average Isn't Good Enough: Identifying Meaningful Subgroups in Clinical Data. Cogn. Ther. Res. 48, 537–551. https://doi.org/10.1007/s10608-023-10453-x

Guan, X., Dong, Z.-Q., Hao, Y.-N., Shen, X.-L., Xie, Q.-L., Chen, J.-M., 2022. Plasma levels of interleukin-8 and response to paroxetine in patients with major depressive disorder. Hum. Psychopharmacol. Clin. Exp. 37, e2855. https://doi.org/10.1002/hup.2855

Hamed, R., Elmalt, H., Salama, AbeerA.A., Abozaid, S., Abd Elaziz, S., 2020. Role of matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitors of metalloproteinase-1 in recurrent depression. Sci. J. Al-Azhar Med. Fac. Girls 4, 295. https://doi.org/10.4103/sjamf.sjamf_51_20

Han, L., Yan, J., Li, T., Lin, W., Huang, Yao, Shen, P., Ba, X., Huang, Ying, Qin, K., Geng, Y., Wang, H., Zheng, K., Liu, Y., Wang, Y., Chen, Z., Tu, S., 2023. Multifaceted oncostatin M: novel roles and therapeutic potential of the oncostatin M signaling in rheumatoid arthritis. Front. Immunol. 14. https://doi.org/10.3389/fimmu.2023.1258765

Hengartner, M.P., Jakobsen, J.C., Sørensen, A., Plöderl, M., 2020. Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. PLOS ONE 15, e0229381. https://doi.org/10.1371/journal.pone.0229381

Jeenger, J., Sharma, M., Mathur, D.M., Amandeep, 2017. Associations of number and severity of depressive episodes with C-reactive protein and Interleukin-6. Asian J. Psychiatry 27, 71–75. https://doi.org/10.1016/j.ajp.2017.02.016

Jha, M., Trivedi, M., 2018. Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation. Int. J. Mol. Sci. 19, 233. https://doi.org/10.3390/ijms19010233

Kennedy, R.H., Silver, R., 2016. Neuroimmune Signaling: Cytokines and the CNS, in: Pfaff, D.W., Volkow, N.D. (Eds.), Neuroscience in the 21st Century. Springer, New York, NY, pp. 1–41. https://doi.org/10.1007/978-1-4614-6434-1_174-1

Knight, D., 2022. Oncostatin M, in: Janes, S.M. (Ed.), Encyclopedia of Respiratory Medicine (Second Edition). Academic Press, Oxford, pp. 723–727. https://doi.org/10.1016/B978-0-08-102723-3.00238-9

Köhler-Forsberg, O., Buttenschøn, H.N., Tansey, K.E., Maier, W., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., Farmer, A., Rietschel, M., McGuffin, P., Aitchison, K.J., Uher, R., Mors,

O., 2017. Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain. Behav. Immun. 62, 344–350. https://doi.org/10.1016/j.bbi.2017.02.020

Lan, X., Zhou, Y., Wu, F., Wu, K., Zhan, Y., Wang, C., Zheng, W., Yu, M., Deng, X., Ning, Y., 2021. The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder. J. Affect. Disord. 287, 327–333. https://doi.org/10.1016/j.jad.2021.03.036

Lee, J., Joo, E.-J., Lim, H.-J., Park, J.-M., Lee, K.Y., Park, A., Seok, A., Lee, H., Kang, H.-G., 2015. Proteomic Analysis of Serum from Patients with Major Depressive Disorder to Compare Their Depressive and Remission Statuses. Psychiatry Investig. 12, 249–259. https://doi.org/10.4306/pi.2015.12.2.249

Lee, N.A., Kung, S., Hu, Y., Greenwaldt, S.E., Lapid, M.I., Croarkin, P.E., 2023. Depression and anxiety outcomes of adults undergoing intermittent theta burst stimulation (iTBS) treatment for major depressive disorder: A naturalistic study. J. Mood Anxiety Disord. 3. https://doi.org/10.1016/j.xjmad.2023.100028

Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S.S., Baeken, C., Benninger, D.H., Cantello, R.M., Cincotta, M., de Carvalho, M., De Ridder, D., Devanne, H., Di Lazzaro, V., Filipović, S.R., Hummel, F.C., Jääskeläinen, S.K., Kimiskidis, V.K., Koch, G., Langguth, B., Nyffeler, T., Oliviero, A., Padberg, F., Poulet, E., Rossi, S., Rossini, P.M., Rothwell, J.C., Schönfeldt-Lecuona, C., Siebner, H.R., Slotema, C.W., Stagg, C.J., Valls-Sole, J., Ziemann, U., Paulus, W., Garcia-Larrea, L., 2014. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol. 125, 2150–2206. https://doi.org/10.1016/j.clinph.2014.05.021

Liu, J.J., Wei, Y.B., Strawbridge, R., Bao, Y., Chang, S., Shi, L., Que, J., Gadad, B.S., Trivedi, M.H., Kelsoe, J.R., Lu, L., 2020. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol. Psychiatry 25, 339–350. https://doi.org/10.1038/s41380-019-0474-5

Mank, V., Azhar, W., Brown, K., 2025. Leukocytosis, in: StatPearls. StatPearls Publishing, Treasure Island (FL).

Martins, C., Neves, B., Teixeira, A.S., Froes, M., Sarmento, P., Machado, J., Magalhães, C.A., Silva, N.A., Silva, M.J., Leite, F., 2024. Identifying subgroups in heart failure patients with multimorbidity by clustering and network analysis. BMC Med. Inform. Decis. Mak. 24, 95. https://doi.org/10.1186/s12911-024-02497-0

Mesleh, A.G., Abdulla, S.A., El-Agnaf, O., 2021. Paving the Way toward Personalized Medicine: Current Advances and Challenges in Multi-OMICS Approach in Autism Spectrum Disorder for Biomarkers Discovery and Patient Stratification. J. Pers. Med. 11, 41. https://doi.org/10.3390/jpm11010041

Milenkovic, V.M., Stanton, E.H., Nothdurfter, C., Rupprecht, R., Wetzel, C.H., 2019. The Role of Chemokines in the Pathophysiology of Major Depressive Disorder. Int. J. Mol. Sci. 20, 2283. https://doi.org/10.3390/ijms20092283

Miller, A.H., Raison, C.L., 2016. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16, 22–34. https://doi.org/10.1038/nri.2015.5

Modur, V., Feldhaus, M.J., Weyrich, A.S., Jicha, D.L., Prescott, S.M., Zimmerman, G.A., McIntyre, T.M., 1997. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J. Clin. Invest. 100, 158–168. https://doi.org/10.1172/JCI119508

Montgomery, S.A., Åsberg, M., 1979. A New Depression Scale Designed to be Sensitive to Change. Br. J. Psychiatry 134, 382–389. https://doi.org/10.1192/bjp.134.4.382

Nehring, S.M., Goyal, A., Patel, B.C., 2025. C Reactive Protein, in: StatPearls. StatPearls Publishing, Treasure Island (FL).

Neuteboom, D., Zantvoord, J.B., Goya-Maldonado, R., Wilkening, J., Dols, A., van Exel, E., Lok, A., de Haan, L., Scheepstra, K.W.F., 2023. Accelerated intermittent theta burst stimulation in major depressive disorder: A systematic review. Psychiatry Res. 327, 115429. https://doi.org/10.1016/j.psychres.2023.115429

O'Brien, S.M., Scully, P., Fitzgerald, P., Scott, L.V., Dinan, T.G., 2007. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41, 326–331. https://doi.org/10.1016/j.jpsychires.2006.05.013

Orsolini, L., Pompili, S., Tempia Valenta, S., Salvi, V., Volpe, U., 2022. C-Reactive Protein as a Biomarker for Major Depressive Disorder? Int. J. Mol. Sci. 23, 1616. https://doi.org/10.3390/ijms23031616

Paganin, W., Signorini, S., 2024. Inflammatory biomarkers in depression: scoping review. BJPsych Open 10, e165. https://doi.org/10.1192/bjo.2024.787

Pardo, A., Selman, M., 2005. MMP-1: the elder of the family. Int. J. Biochem. Cell Biol. 37, 283–288. https://doi.org/10.1016/j.biocel.2004.06.017

Pedraz-Petrozzi, B., Insan, S., Spangemacher, M., Reinwald, J., Lamadé, E.K., Gilles, M., Deuschle, M., Sartorius, A., 2024. Association between rTMS-induced changes in inflammatory markers and improvement in psychiatric diseases: a systematic review. Ann. Gen. Psychiatry 23, 31. https://doi.org/10.1186/s12991-024-00514-0

Raison, C.L., Miller, A.H., 2011. Is Depression an Inflammatory Disorder? Curr. Psychiatry Rep. 13, 467–475. https://doi.org/10.1007/s11920-011-0232-0

Richards, C.D., 2013. The Enigmatic Cytokine Oncostatin M and Roles in Disease. Int. Sch. Res. Not. 2013, 512103. https://doi.org/10.1155/2013/512103

Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905

Schmidt, F.M., Kirkby, K.C., Lichtblau, N., 2016. Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment. Curr. Neuropharmacol. 14, 674–687. https://doi.org/10.2174/1570159x14666160115130414

Shibasaki, C., Takebayashi, M., Itagaki, K., Abe, H., Kajitani, N., Okada-Tsuchioka, M., Yamawaki, S., 2016. Altered Serum Levels of Matrix Metalloproteinase-2, -9 in Response to Electroconvulsive Therapy for Mood Disorders. Int. J. Neuropsychopharmacol. 19, pyw019. https://doi.org/10.1093/ijnp/pyw019

Steiner, J., Guest, P.C., Rahmoune, H., Martins-de-Souza, D., 2017. The Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients, in: Guest, P.C. (Ed.), Multiplex Biomarker Techniques: Methods and Applications. Springer, New York, NY, pp. 19–35. https://doi.org/10.1007/978-1-4939-6730-8_2

Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., Cleare, A.J., 2015. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur. Neuropsychopharmacol. 25, 1532–1543. https://doi.org/10.1016/j.euroneuro.2015.06.007

Strawbridge, R., Hodsoll, J., Powell, T.R., Hotopf, M., Hatch, S.L., Breen, G., Cleare, A.J., 2019. Inflammatory profiles of severe treatment-resistant depression. J. Affect. Disord. 246, 42–51. https://doi.org/10.1016/j.jad.2018.12.037

Stuart, M.J., Singhal, G., Baune, B.T., 2015. Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders. Front. Cell. Neurosci. 9. https://doi.org/10.3389/fncel.2015.00357

Syed, S.A., Beurel, E., Loewenstein, D.A., Lowell, J.A., Craighead, W.E., Dunlop, B.W., Mayberg, H.S., Dhabhar, F., Dietrich, W.D., Keane, R.W., De Rivero Vaccari, J.P., Nemeroff, C.B., 2018. Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. Neuron 99, 914-924.e3. https://doi.org/10.1016/j.neuron.2018.08.001

Tanaka, M., Miyajima, A., 2003. Oncostatin M, a multifunctional cytokine. Rev. Physiol. Biochem. Pharmacol. 149, 39–52. https://doi.org/10.1007/s10254-003-0013-1

Tse, N.Y., Goldsworthy, M.R., Ridding, M.C., Coxon, J.P., Fitzgerald, P.B., Fornito, A., Rogasch, N.C., 2018. The effect of stimulation interval on plasticity following repeated blocks of intermittent theta burst stimulation. Sci. Rep. 8, 8526. https://doi.org/10.1038/s41598-018-26791-w

Uher, R., Tansey, K.E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., Farmer, A., McGuffin, P., 2014. An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. Am. J. Psychiatry 171, 1278–1286. https://doi.org/10.1176/appi.ajp.2014.14010094

Voelker, J., Wang, K., Tang, W., He, J., Daly, E., Pericone, C.D., Sheehan, J.J., 2021. Association of depression symptom severity with short-term risk of an initial hospital encounter in adults with major depressive disorder. BMC Psychiatry 21, 257. https://doi.org/10.1186/s12888-021-03258-3

Voßhenrich, C.A.J., Santo, J.P.D., 2002. Interleukin signaling. Curr. Biol. 12, R760–R763. https://doi.org/10.1016/S0960-9822(02)01286-1

Wilkening, J., Goya-Maldonado, R., 2025. White matter tracts associated with iTBS-induced heart rate deceleration and treatment response in major depressive disorder. https://doi.org/10.1101/2025.01.09.25320274

Wilkening, J., Jungeblut, H.M., Adamovic, I., Belov, V., Dechent, P., Eicke, L., Hansen, N., Kozyrev, V., Marten, L.E., Muschke, Y., Riemer, C., Schnell, K., Tura, A., Wilke, M., Witteler, F., Wiltfang, J., Wunderlich, A., Zimmeck, V., Zobott, A., Schmidt-Samoa, C., Erwin-Grabner, T., Goya-Maldonado, R., 2025. Heart Rate Modulation and Clinical Improvement in Major Depression: A Randomized Clinical Trial with Accelerated Intermittent Theta Burst Stimulation. https://doi.org/10.1101/2025.04.06.25325324

Wilkening, J., Witteler, F., Goya-Maldonado, R., 2022. Suicidality and relief of depressive symptoms with intermittent theta burst stimulation in a sham-controlled randomized clinical trial. Acta Psychiatr. Scand. 146, 540–556. https://doi.org/10.1111/acps.13502

World Health Organization, 2017. Depression and other common mental disorders: global health estimates (Technical documents). World Health Organization.

Yang, C., Wardenaar, K.J., Bosker, F.J., Li, J., Schoevers, R.A., 2019. Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review. J. Affect. Disord. 257, 640–649. https://doi.org/10.1016/j.jad.2019.07.045

Yang, L., Cao, M., Tian, J., Cui, P., Ai, L., Li, X., Li, H., Gao, M., Fang, L., Zhao, L., Gong, F., Zhou, C., 2023. Identification of Plasma Inflammatory Markers of Adolescent Depression Using the Olink Proteomics Platform. J. Inflamm. Res. 16, 4489–4501. https://doi.org/10.2147/JIR.S425780

Yilmaz, N.S., Sen, B., Karadag, R.F., Aslan, S., Ekmekci Ertek, I., Bozkurt, A., Cicek, S., Bolu, A., Ucar, H., Kocak, C., Cevik, C., Bukan, N., 2022. A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response: a pilot study. J. Neural Transm. Vienna Austria 1996 129, 1513–1526. https://doi.org/10.1007/s00702-022-02553-x

Yoshimura, T., Matsushima, K., Oppenheim, J.J., Leonard, E.J., 1987. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J. Immunol. Baltim. Md 1950 139, 788–793.

Zimmerman, M., Balling, C., Chelminski, I., Dalrymple, K., 2018. Understanding the severity of depression: Which symptoms of depression are the best indicators of depression severity? Compr. Psychiatry 87, 84–88. https://doi.org/10.1016/j.comppsych.2018.09.006

Volcano Plot